secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0000950170-25-004168
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology enters amended employment agreements with CEO, President, and three other executives with enhanced severance
--------------------------------------------------------------------------------

- CEO Arthur Kuan and President/COO Ambaw Bellete: 1.5x salary + prorated bonus outside CIC; 2.0x salary + full bonus inside CIC.
- COBRA premium payments for up to 18 months (CIC: 24 months) and 18-month equity acceleration (CIC: full vesting).
- Bellete's June 2023 option of 432,311 shares gets full accelerated vesting after second anniversary on termination without cause outside CIC.
- CMO Kasturi, CFO Roche, GC Patterson: 1.0x salary + 12-month COBRA outside CIC; 1.5x salary + 18-month COBRA inside CIC.
- All agreements dated January 9, 2025; full text to be filed in 2024 Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025004168/0000950170-25-004168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025004168/ck0001991792-20250109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer